---
document_datetime: 2025-12-02 05:50:37
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/sprycel.html
document_name: sprycel.html
version: success
processing_time: 0.1346943
conversion_datetime: 2025-12-26 16:59:55.663694
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Sprycel

[RSS](/en/individual-human-medicine.xml/66480)

##### Authorised

This medicine is authorised for use in the European Union

dasatinib (anhydrous) Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Sprycel](#news-on)
- [More information on Sprycel](#more-information-on-sprycel-709)
- [More information on Sprycel](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Sprycel is a cancer medicine. It is used to treat adults with the following types of leukaemia (cancer of the white blood cells):

- chronic myeloid leukaemia (CML) in the 'chronic' phase in newly diagnosed patients who are 'Philadelphia chromosome positive' (Ph+). In CML, granulocytes (a type of white blood cell) start growing out of control. Ph+ means that some of the patient's genes have rearranged themselves to form a special chromosome called the Philadelphia chromosome which produces an enzyme, Bcr-Abl kinase that leads to the development of leukaemia.
- CML in 'chronic', 'accelerated' and 'blast' phases. Sprycel is used when other treatments including imatinib (another cancer medicine) do not work or cause troublesome side effects;
- Ph+ acute lymphoblastic leukaemia (ALL), where lymphocytes (another type of white blood cell) multiply too quickly, or in 'lymphoid blast' CML. Sprycel is used when other treatments do not work or cause troublesome side effects.

Sprycel is also used in children to treat:

- newly diagnosed Ph+ CML in the 'chronic' phase, or Ph+ CML when other treatments including imatinib cannot be given or have not worked;
- newly diagnosed Ph+ ALL in combination with chemotherapy (cancer medicines).

Sprycel contains the active substance dasatinib.

Expand section

Collapse section

## How is Sprycel used?

Sprycel can only be obtained with a prescription and treatment should be started by a doctor who has experience in the diagnosis and treatment of leukaemia.

Sprycel is available as tablets (20, 50, 70, 80, 100 and 140 mg) and a powder to make up a suspension (10 mg/ml) to be taken by mouth. It is taken once a day, consistently either in the morning or in the evening. The doses for Sprycel tablets and suspension are not the same.

The starting dose depends on the condition being treated and, for children, their body weight. The dose is then gradually increased until the disease is controlled well enough. In children with ALL who are also receiving other cancer medicines, a fixed dose of Sprycel is used throughout their treatment. The doctor may reduce the dose or interrupt treatment if blood cell counts are too low or certain side effects occur. Treatment is stopped if the medicine no longer controls the condition or if the patient cannot take the medicine because of side effects.

For more information about using Sprycel, see the package leaflet or contact your doctor or pharmacist.

## How does Sprycel work?

The active substance in Sprycel, dasatinib, belongs to a group of medicines that block enzymes known as protein kinases. Dasatinib acts mainly by blocking the Bcr?Abl protein kinase. This enzyme is produced by leukaemia cells, and causes them to multiply uncontrollably. By blocking Bcr?Abl kinase, as well as other kinases, Sprycel helps to reduce the number of leukaemia cells.

## What benefits of Sprycel have been shown in studies?

The five main studies of Sprycel in adults involved 515 patients, all of whom had received treatment with imatinib, which had not worked or had stopped working. None of these studies compared Sprycel with another medicine. Most of these studies assessed how well the leukaemia responded to treatment by measuring the levels of white cells and platelets in the blood, to see if they were returning to within normal levels, and by measuring the number of white blood cells that contained the Philadelphia chromosome, to see if it was decreasing.

Two studies were in patients with chronic CML (198 and 36 patients), one was in accelerated CML (120 patients), one was in myeloid blast CML (80 patients), and one was in Ph+ ALL and lymphoid blast CML (81 patients).

In the larger main study of patients with chronic phase CML, blood levels of platelets and white blood cells returned to within normal values in 90% of the patients. In patients with CML in other phases (accelerated, myeloid blast and lymphoid blast) and in ALL, around 25 to 33% of the patients had complete response. In addition, the number of white blood cells containing the Philadelphia chromosome was reduced in around 33 to 66% of treated patients in the five main studies.

Two further studies compared the effects of Sprycel taken once or twice a day, one in 670 patients with chronic phase CML and the other in 611 patients with advanced phase CML or Ph+ ALL. Once- and twice-daily Sprycel had similar effectiveness, but the once-daily dose caused fewer side effects.

A further study involving 519 patients compared Sprycel with imatinib in treating newly diagnosed Ph+ patients with chronic phase CML who had not received any previous treatment. Sprycel was more effective than imatinib: within one year, 77% of patients receiving Sprycel no longer had the Philadelphia chromosome in their blood cells, compared with 66% of patients receiving imatinib.

Another main study looked at the effectiveness of Sprycel in 113 children with Ph+ chronic phase CML, including 29 patients who could not use imatinib or it had not worked, as well as 84 newly diagnosed children who had not been previously treated. A response was seen in around 90% of patients who could not use imatinib or it had not worked, and in 94% of newly diagnosed patients.

In a study involving 106 children and adolescents with newly diagnosed Ph+ ALL, patients were treated with Sprycel and chemotherapy. The main measure of effectiveness was the proportion of patients who did not have an unwanted event within 3 years of treatment. Such events were: any sign of the disease in bone marrow, return of the disease anywhere in the body, a second cancer or death. Among patients treated with Sprycel and chemotherapy, 66% did not have an unwanted event. In comparison, using results of previous studies, the figure was 49% in patients who had received chemotherapy alone and 59% in patients who had received imatinib and chemotherapy.

## What are the risks associated with Sprycel?

The most common side effects with Sprycel (seen in more than 1 patient in 10) are infection, suppression of the bone marrow (decreasing numbers of blood cells), headache, haemorrhage (bleeding), pleural effusion (fluid around the lungs), dyspnoea (difficulty breathing), diarrhoea, vomiting, nausea (feeling sick), abdominal pain (belly ache), skin rash, musculoskeletal pain, tiredness, swelling in the legs and arms and in the face, fever. For the full list of side effects and restrictions with Sprycel, see the package leaflet.

## Why is Sprycel authorised in the EU?

The European Medicines Agency decided that Sprycel's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Sprycel?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Sprycel have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Sprycel are continuously monitored. Side effects reported with Sprycel are carefully evaluated and any necessary action taken to protect patients.

## Other information about Sprycel

Sprycel received a marketing authorisation valid throughout the European Union on 20 November 2006.

Sprycel : EPAR - Medicine overview

English (EN) (87.85 KB - PDF)

**First published:** 18/08/2009

**Last updated:** 29/03/2019

[View](/en/documents/overview/sprycel-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-240)

български (BG) (117.94 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

29/03/2019

[View](/bg/documents/overview/sprycel-epar-medicine-overview_bg.pdf)

español (ES) (88.7 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

29/03/2019

[View](/es/documents/overview/sprycel-epar-medicine-overview_es.pdf)

čeština (CS) (117.2 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

29/03/2019

[View](/cs/documents/overview/sprycel-epar-medicine-overview_cs.pdf)

dansk (DA) (87.14 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

29/03/2019

[View](/da/documents/overview/sprycel-epar-medicine-overview_da.pdf)

Deutsch (DE) (91.11 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

29/03/2019

[View](/de/documents/overview/sprycel-epar-medicine-overview_de.pdf)

eesti keel (ET) (87.66 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

29/03/2019

[View](/et/documents/overview/sprycel-epar-medicine-overview_et.pdf)

ελληνικά (EL) (120.39 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

29/03/2019

[View](/el/documents/overview/sprycel-epar-medicine-overview_el.pdf)

français (FR) (89.83 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

29/03/2019

[View](/fr/documents/overview/sprycel-epar-medicine-overview_fr.pdf)

hrvatski (HR) (112.45 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

29/03/2019

[View](/hr/documents/overview/sprycel-epar-medicine-overview_hr.pdf)

italiano (IT) (87.84 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

29/03/2019

[View](/it/documents/overview/sprycel-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (114.44 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

29/03/2019

[View](/lv/documents/overview/sprycel-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (113.95 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

29/03/2019

[View](/lt/documents/overview/sprycel-epar-medicine-overview_lt.pdf)

magyar (HU) (110.27 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

29/03/2019

[View](/hu/documents/overview/sprycel-epar-medicine-overview_hu.pdf)

Malti (MT) (117.46 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

29/03/2019

[View](/mt/documents/overview/sprycel-epar-medicine-overview_mt.pdf)

Nederlands (NL) (87.76 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

29/03/2019

[View](/nl/documents/overview/sprycel-epar-medicine-overview_nl.pdf)

polski (PL) (113.97 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

29/03/2019

[View](/pl/documents/overview/sprycel-epar-medicine-overview_pl.pdf)

português (PT) (88.94 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

29/03/2019

[View](/pt/documents/overview/sprycel-epar-medicine-overview_pt.pdf)

română (RO) (114.6 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

29/03/2019

[View](/ro/documents/overview/sprycel-epar-medicine-overview_ro.pdf)

slovenčina (SK) (116.06 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

29/03/2019

[View](/sk/documents/overview/sprycel-epar-medicine-overview_sk.pdf)

slovenščina (SL) (109.77 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

29/03/2019

[View](/sl/documents/overview/sprycel-epar-medicine-overview_sl.pdf)

Suomi (FI) (87.86 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

29/03/2019

[View](/fi/documents/overview/sprycel-epar-medicine-overview_fi.pdf)

svenska (SV) (87.97 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

29/03/2019

[View](/sv/documents/overview/sprycel-epar-medicine-overview_sv.pdf)

Sprycel : EPAR - Risk-management-plan summary

English (EN) (242.71 KB - PDF)

**First published:** 29/03/2019

[View](/en/documents/rmp-summary/sprycel-epar-risk-management-plan-summary_en.pdf)

Sprycel : EPAR - Risk management plan

English (EN) (6 MB - PDF)

**First published:** 30/10/2023

**Last updated:** 18/06/2025

[View](/en/documents/rmp/sprycel-epar-risk-management-plan_en.pdf)

## Product information

Sprycel : EPAR - Product Information

English (EN) (1.39 MB - PDF)

**First published:** 18/08/2009

**Last updated:** 15/05/2025

[View](/en/documents/product-information/sprycel-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-9)

български (BG) (1.95 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

15/05/2025

[View](/bg/documents/product-information/sprycel-epar-product-information_bg.pdf)

español (ES) (1.72 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

15/05/2025

[View](/es/documents/product-information/sprycel-epar-product-information_es.pdf)

čeština (CS) (1.92 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

15/05/2025

[View](/cs/documents/product-information/sprycel-epar-product-information_cs.pdf)

dansk (DA) (1.77 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

15/05/2025

[View](/da/documents/product-information/sprycel-epar-product-information_da.pdf)

Deutsch (DE) (1.82 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

15/05/2025

[View](/de/documents/product-information/sprycel-epar-product-information_de.pdf)

eesti keel (ET) (1.69 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

15/05/2025

[View](/et/documents/product-information/sprycel-epar-product-information_et.pdf)

ελληνικά (EL) (1.95 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

15/05/2025

[View](/el/documents/product-information/sprycel-epar-product-information_el.pdf)

français (FR) (1.86 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

15/05/2025

[View](/fr/documents/product-information/sprycel-epar-product-information_fr.pdf)

hrvatski (HR) (1.87 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

15/05/2025

[View](/hr/documents/product-information/sprycel-epar-product-information_hr.pdf)

íslenska (IS) (1.69 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

15/05/2025

[View](/is/documents/product-information/sprycel-epar-product-information_is.pdf)

italiano (IT) (1.74 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

15/05/2025

[View](/it/documents/product-information/sprycel-epar-product-information_it.pdf)

latviešu valoda (LV) (1.89 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

15/05/2025

[View](/lv/documents/product-information/sprycel-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.9 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

15/05/2025

[View](/lt/documents/product-information/sprycel-epar-product-information_lt.pdf)

magyar (HU) (2.02 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

15/05/2025

[View](/hu/documents/product-information/sprycel-epar-product-information_hu.pdf)

Malti (MT) (2.24 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

15/05/2025

[View](/mt/documents/product-information/sprycel-epar-product-information_mt.pdf)

Nederlands (NL) (1.75 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

15/05/2025

[View](/nl/documents/product-information/sprycel-epar-product-information_nl.pdf)

norsk (NO) (1.79 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

15/05/2025

[View](/no/documents/product-information/sprycel-epar-product-information_no.pdf)

polski (PL) (1.92 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

15/05/2025

[View](/pl/documents/product-information/sprycel-epar-product-information_pl.pdf)

português (PT) (1.76 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

15/05/2025

[View](/pt/documents/product-information/sprycel-epar-product-information_pt.pdf)

română (RO) (1.86 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

15/05/2025

[View](/ro/documents/product-information/sprycel-epar-product-information_ro.pdf)

slovenčina (SK) (1.97 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

15/05/2025

[View](/sk/documents/product-information/sprycel-epar-product-information_sk.pdf)

slovenščina (SL) (1.88 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

15/05/2025

[View](/sl/documents/product-information/sprycel-epar-product-information_sl.pdf)

Suomi (FI) (1.9 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

15/05/2025

[View](/fi/documents/product-information/sprycel-epar-product-information_fi.pdf)

svenska (SV) (1.75 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

15/05/2025

[View](/sv/documents/product-information/sprycel-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000254764 14/05/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Sprycel : EPAR - All Authorised presentations

English (EN) (55.9 KB - PDF)

**First published:** 04/02/2009

**Last updated:** 09/07/2018

[View](/en/documents/all-authorised-presentations/sprycel-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-651)

български (BG) (80.47 KB - PDF)

**First published:**

04/02/2009

**Last updated:**

09/07/2018

[View](/bg/documents/all-authorised-presentations/sprycel-epar-all-authorised-presentations_bg.pdf)

español (ES) (86.29 KB - PDF)

**First published:**

04/02/2009

**Last updated:**

09/07/2018

[View](/es/documents/all-authorised-presentations/sprycel-epar-all-authorised-presentations_es.pdf)

čeština (CS) (81.12 KB - PDF)

**First published:**

04/02/2009

**Last updated:**

09/07/2018

[View](/cs/documents/all-authorised-presentations/sprycel-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (56.03 KB - PDF)

**First published:**

04/02/2009

**Last updated:**

09/07/2018

[View](/da/documents/all-authorised-presentations/sprycel-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (55.95 KB - PDF)

**First published:**

04/02/2009

**Last updated:**

09/07/2018

[View](/de/documents/all-authorised-presentations/sprycel-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (55.02 KB - PDF)

**First published:**

04/02/2009

**Last updated:**

09/07/2018

[View](/et/documents/all-authorised-presentations/sprycel-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (73.94 KB - PDF)

**First published:**

04/02/2009

**Last updated:**

09/07/2018

[View](/el/documents/all-authorised-presentations/sprycel-epar-all-authorised-presentations_el.pdf)

français (FR) (56.09 KB - PDF)

**First published:**

04/02/2009

**Last updated:**

09/07/2018

[View](/fr/documents/all-authorised-presentations/sprycel-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (71.34 KB - PDF)

**First published:**

04/02/2009

**Last updated:**

09/07/2018

[View](/hr/documents/all-authorised-presentations/sprycel-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (53.44 KB - PDF)

**First published:**

04/02/2009

**Last updated:**

09/07/2018

[View](/is/documents/all-authorised-presentations/sprycel-epar-all-authorised-presentations_is.pdf)

italiano (IT) (55.06 KB - PDF)

**First published:**

04/02/2009

**Last updated:**

09/07/2018

[View](/it/documents/all-authorised-presentations/sprycel-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (85.1 KB - PDF)

**First published:**

04/02/2009

**Last updated:**

09/07/2018

[View](/lv/documents/all-authorised-presentations/sprycel-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (96.66 KB - PDF)

**First published:**

04/02/2009

**Last updated:**

09/07/2018

[View](/lt/documents/all-authorised-presentations/sprycel-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (69.66 KB - PDF)

**First published:**

04/02/2009

**Last updated:**

09/07/2018

[View](/hu/documents/all-authorised-presentations/sprycel-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (70.21 KB - PDF)

**First published:**

04/02/2009

**Last updated:**

09/07/2018

[View](/mt/documents/all-authorised-presentations/sprycel-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (51.68 KB - PDF)

**First published:**

04/02/2009

**Last updated:**

09/07/2018

[View](/nl/documents/all-authorised-presentations/sprycel-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (56.21 KB - PDF)

**First published:**

04/02/2009

**Last updated:**

09/07/2018

[View](/no/documents/all-authorised-presentations/sprycel-epar-all-authorised-presentations_no.pdf)

polski (PL) (83.43 KB - PDF)

**First published:**

04/02/2009

**Last updated:**

09/07/2018

[View](/pl/documents/all-authorised-presentations/sprycel-epar-all-authorised-presentations_pl.pdf)

português (PT) (56.82 KB - PDF)

**First published:**

04/02/2009

**Last updated:**

09/07/2018

[View](/pt/documents/all-authorised-presentations/sprycel-epar-all-authorised-presentations_pt.pdf)

română (RO) (80.67 KB - PDF)

**First published:**

04/02/2009

**Last updated:**

09/07/2018

[View](/ro/documents/all-authorised-presentations/sprycel-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (83.56 KB - PDF)

**First published:**

04/02/2009

**Last updated:**

09/07/2018

[View](/sk/documents/all-authorised-presentations/sprycel-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (57.06 KB - PDF)

**First published:**

04/02/2009

**Last updated:**

09/07/2018

[View](/sl/documents/all-authorised-presentations/sprycel-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (54.47 KB - PDF)

**First published:**

04/02/2009

**Last updated:**

09/07/2018

[View](/fi/documents/all-authorised-presentations/sprycel-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (69.81 KB - PDF)

**First published:**

04/02/2009

**Last updated:**

09/07/2018

[View](/sv/documents/all-authorised-presentations/sprycel-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Sprycel Active substance dasatinib International non-proprietary name (INN) or common name dasatinib (anhydrous) Therapeutic area (MeSH)

- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Anatomical therapeutic chemical (ATC) code L01EA02

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Sprycel is indicated for the treatment of paediatric patients with:

- newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase (Ph+ CML CP) or Ph+ CML CP resistant or intolerant to prior therapy including imatinib.
- newly diagnosed Ph+ acute lymphoblastic leukaemia (ALL) in combination with chemotherapy.

Sprycel is indicated for the treatment of adult patients with:

- newly diagnosed Philadelphia-chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase;
- chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate;
- Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.

Sprycel is indicated for the treatment of paediatric patients with:

- newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.

## Authorisation details

EMA product number EMEA/H/C/000709 Marketing authorisation holder

Bristol-Myers Squibb Pharma EEIG

Plaza 254

Opinion adopted 21/09/2006 Marketing authorisation issued 20/11/2006 Revision 45

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Sprycel : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (133.38 KB - PDF)

**First published:** 15/05/2025

[View](/en/documents/procedural-steps-after/sprycel-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Sprycel : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (244.7 KB - PDF)

**First published:** 18/08/2009

**Last updated:** 15/05/2025

[View](/en/documents/procedural-steps-after/sprycel-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Sprycel-PSUSA-00000935-202106 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/176825/2022

English (EN) (123.69 KB - PDF)

**First published:** 21/04/2022

[View](/en/documents/scientific-conclusion/sprycel-psusa-00000935-202106-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Sprycel-H-C-709-P46-048 : EPAR - Assessment report

Adopted

Reference Number: EMA/119741/2022

English (EN) (577.22 KB - PDF)

**First published:** 25/02/2022

[View](/en/documents/variation-report/sprycel-h-c-709-p46-048-epar-assessment-report_en.pdf)

Sprycel-H-C-709-P46-047 : EPAR - Assessment report

Adopted

Reference Number: EMA/500437/2020

English (EN) (715.93 KB - PDF)

**First published:** 16/02/2021

[View](/en/documents/variation-report/sprycel-h-c-709-p46-047-epar-assessment-report_en.pdf)

Sprycel-PSUSA-00000935-201806 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/227269/2019

English (EN) (68.2 KB - PDF)

**First published:** 16/04/2019

[View](/en/documents/scientific-conclusion/sprycel-psusa-00000935-201806-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Sprycel-H-C-709-II-0059 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/3851/2019

English (EN) (6.26 MB - PDF)

**First published:** 29/03/2019

[View](/en/documents/variation-report/sprycel-h-c-709-ii-0059-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Sprycel (II-59)

Adopted

Reference Number: EMA/CHMP/840868/2018

English (EN) (72.36 KB - PDF)

**First published:** 14/12/2018

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sprycel-ii-59_en.pdf)

Sprycel-H-C-000709-X-0056-G : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/302652/2018

English (EN) (1.9 MB - PDF)

**First published:** 09/07/2018

**Last updated:** 09/07/2018

[View](/en/documents/variation-report/sprycel-h-c-000709-x-0056-g-epar-assessment-report-variation_en.pdf)

Sprycel-H-C-709-P46-0041 : EPAR - Assessment report

Adopted

Reference Number: EMA/725514/2015

English (EN) (3.78 MB - PDF)

**First published:** 17/12/2015

**Last updated:** 17/12/2015

[View](/en/documents/variation-report/sprycel-h-c-709-p46-0041-epar-assessment-report_en.pdf)

Sprycel-H-C-709-PSUV-0041 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/109489/2015

English (EN) (69.38 KB - PDF)

**First published:** 06/08/2015

**Last updated:** 06/08/2015

[View](/en/documents/scientific-conclusion/sprycel-h-c-709-psuv-0041-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Sprycel-H-C-709-A46-0035 : EPAR - Assessment Report

Adopted

Reference Number: EMA/273206/2012

English (EN) (187.92 KB - PDF)

**First published:** 23/05/2012

**Last updated:** 23/05/2012

[View](/en/documents/variation-report/sprycel-h-c-709-a46-0035-epar-assessment-report_en.pdf)

Sprycel-H-709-II-0023 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/761358/2010

English (EN) (403 KB - PDF)

**First published:** 22/12/2010

**Last updated:** 22/12/2010

[View](/en/documents/variation-report/sprycel-h-709-ii-0023-epar-assessment-report-variation_en.pdf)

Sprycel-H-C-709-II-0010 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (372.21 KB - PDF)

**First published:** 13/05/2009

**Last updated:** 13/05/2009

[View](/en/documents/scientific-discussion-variation/sprycel-h-c-709-ii-0010-epar-scientific-discussion-variation_en.pdf)

Sprycel-H-C-709-II-0008 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (285.02 KB - PDF)

**First published:** 01/09/2008

**Last updated:** 01/09/2008

[View](/en/documents/scientific-discussion-variation/sprycel-h-c-709-ii-0008-epar-scientific-discussion-variation_en.pdf)

Sprycel-H-C-709-II-0002 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (197.56 KB - PDF)

**First published:** 27/11/2007

**Last updated:** 27/11/2007

[View](/en/documents/scientific-discussion-variation/sprycel-h-c-709-ii-0002-epar-scientific-discussion-variation_en.pdf)

## Initial marketing authorisation documents

Sprycel : EPAR - Procedural steps taken before authorisation

English (EN) (22.89 KB - PDF)

**First published:** 30/11/2006

**Last updated:** 30/11/2006

[View](/en/documents/procedural-steps/sprycel-epar-procedural-steps-taken-authorisation_en.pdf)

Sprycel : EPAR - Scientific Discussion

English (EN) (349.15 KB - PDF)

**First published:** 30/11/2006

**Last updated:** 30/11/2006

[View](/en/documents/scientific-discussion/sprycel-epar-scientific-discussion_en.pdf)

#### News on Sprycel

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018) 14/12/2018

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-april-2018) 27/04/2018

#### More information on Sprycel

This product is no longer an orphan medicine. It was originally designated an orphan medicine for the following orphan indications:

- [treatment of acute lymphoblastic leukaemia](/en/medicines/human/orphan-designations/eu305338) (23/12/2015);
- [treatment of chronic myeloid leukaemia](/en/medicines/human/orphan-designations/eu305339) (23/12/2015).

Sprycel was withdrawn from the Community register of orphan medicinal products in November 2016 at the end of the 10-year period of market exclusivity.

#### More information on Sprycel

- [EMEA-000567-PIP01-09-M05 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000567-pip01-09-m05)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)
- [Paediatrics](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A65)

**This page was last updated on** 18/06/2025

## Share this page

[Back to top](#main-content)